Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03775928 Recruiting - Clinical trials for Triple-negative Breast Cancer

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Start date: December 18, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer

NCT ID: NCT03775850 Not yet recruiting - Bladder Cancer Clinical Trials

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Start date: December 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

NCT ID: NCT03774472 Recruiting - HER2/Neu Negative Clinical Trials

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Start date: August 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating participants with estrogen receptor positive, HER2 negative breast cancer. Hydroxychloroquine is a substance that decreases immune responses in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving hydroxychloroquine, palbociclib, and letrozole before surgery may work better in treating participants with breast cancer.

NCT ID: NCT03772353 Not yet recruiting - Breast Cancer Clinical Trials

Study to Evaluate Letrozole, Pyrotinib Combined With SHR6390 in Patients With HR+/HER2+ Relapsed/Metastatic Breast Cancer

Start date: December 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center Ib / II study of triple targeted drug combination (aromatase inhibitor letrozole,novel HER2-targeted small molecule inhibitor pyrotinib and CDK4/6 inhibitor SHR6390) as a first or second line of therapy in patients with relapsed/metastatic hormone receptor positive and HER2-positive breast cancer.

NCT ID: NCT03772197 Completed - Breast Cancer Clinical Trials

Parallel Comparison of 18 Gene Classifiers and Oncotype DX:A Retrospective Study (Nanostring Platform)

Start date: June 1, 2018
Study type: Observational

A recurrence index for distant recurrence (RI-DR), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (EBC). In this study, we compared the prognostic performance of the RI-DR with the Oncotype DX (ODx) recurrence score (RS) for any recurrence risk type.

NCT ID: NCT03771183 Not yet recruiting - Clinical trials for Breast Cancer Patients

Loreline Study: Characterization of Long Responders Under Eribuline

Start date: January 2019
Study type: Observational

There is currently no strict recommendations for the management of patients who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy for advanced breast cancer. However, Halaven® can represent a therapeutic alternative at this stage of the disease. Indeed, since march 2011, Halaven® has been granted Marketing Authorization (MA) for patients with metastatic or locally advanced breast cancer, whose disease has progressed after at least two lines of chemotherapy for advanced disease (3rd line). In these patients, the indication for marketing authorization specifies that the previous treatment must have included an anthracycline and a taxane except in patients who can not receive these treatments. An extension of indication was obtained on 27/06/2014 with a marketing authorization obtained in the treatment of locally advanced or second-line metastatic breast cancer. According to the Transparency Commission of the High Authority of Health (HAS dated September 23, 2015), Halaven® (Eribulin), administered as monotherapy, in the third line of treatment and beyond, represents a therapeutic option, because it brings an improvement of medical service rendered compared to Capecitabine (XELODA®) and Vinorelbine (NAVELBINE®). In addition, Halaven® (Eribuline) administrated as monotherapy in second-line of treatment is an alternative to other monotherapies recommended for the treatment of locally advanced or metastatic relapsed breast cancer, such as Capecitabine (XELODA®). and Vinorelbine (NAVELBINE®). But, no improvement of medical service rendered has been reported in second line of treatment. According to these results, it would be interesting to have additional data concerning the use of Halaven® (Eribulin), in the second and third lines, but also in the fourth line. For this purpose, the investigators propose to perform a study in patients with metastatic breast cancer who have failed treatment after the first line and beyond. In this study, the investigators will be particularly interested in "long-responder" patients, that is to say, in objective response or with stability for 6 months or more under Halaven®, in order to better characterize these patients. Patients must have been treated by Halaven between September 2011 and December 2016, to have a sufficient follow-up for the survival data of the patients.

NCT ID: NCT03770598 Recruiting - Breast Cancer Clinical Trials

Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients

Start date: November 28, 2018
Phase: N/A
Study type: Interventional

Researchers are trying to see if proactive identification and team based individualized care of cancer patients having emotional difficulties can improve quality of life relative to treatment as usual. Also, to see if proactive approaches to maintain wellness can prevent grief among breast cancer patients, experiencing no emotional difficulties relative to treatment as usual.

NCT ID: NCT03769428 Not yet recruiting - Clinical trials for Postoperative Analgesia

The Erector Spinae Plane Block: a Novel Technique for Postoperative Analgesia in Breast Cancer Surgery

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Breast cancer surgery is one of the most common surgeries, due to the high incidence of breast cancer. Unfortunately, patients experience significant postoperative acute pain, placing them at risk for increased clinical morbidity and the development of disabling chronic pain which may rich up to 55% . The intensity of perioperative pain experienced by the patient is one of the best predictors of chronic pain. However, postoperative analgesia in breast cancer surgery is difficult due to the extensive nature of the surgery and the complex innervation of the breast. Several newly described regional anesthesia techniques exist to control perioperative pain, including the Paravertebral block (PVB) which has been proved to be the most effective one. The anatomic proximity of the pleura and central neuraxial system makes it a particularly challenging technique and carrying a risk of pneumothorax. The Erector Spinae Plane Block (ESPB) is a novel interfascial plane block described by Forero et al in September 2016. Local anesthetic injection is performed beneath the erector spinae muscle. Local anesthetic (LA) expected to achieve paravertebral spread of three vertebral levels cranially and four levels caudally, blocking the dorsal and ventral rami of the spinal nerves.The easy, fast and safe execution of ESPB makes it a promising technique in the context of surgical pain during breast cancer surgery. There is no sufficient randomized controlled trials that assess the effectiveness of ESPB in controlling post-operative breast surgery pain. The main purpose of this study is to evaluate the postoperative analgesic effect of Ultrasound-guided ESPB in patients undergoing breast cancer surgery.

NCT ID: NCT03769415 Recruiting - Breast Cancer Clinical Trials

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Start date: November 6, 2018
Phase: N/A
Study type: Interventional

The HARMONY trial is an interventional trial designed to determine the impact of molecular information on clinical decision-making in metastatic breast cancer (MBC). HARMONY will enroll incident MBC patients. We will perform intrinsic subtype on the primary tumor using the PAM50 methodology in a CLIA-compliant setting and provide these data to the treating physician. In this way we will identify the congruence rates between expected and observed subtype based on clinical phenotype (e.g. luminal biology in a hormone receptor-positive tumor), survey the treating physicians regarding the impact of this biologic information on treatment decisions, and examine progression-free survival on concordant vs discordant treatment regimens. We will also examine other gene expression signatures related to tumor behavior and immune activation including signatures developed to characterize tumor-immune interaction and will perform RNA sequencing, however the results of those assays will be analyzed in an integrated fashion and will not be provided to the treating physician.

NCT ID: NCT03768492 Not yet recruiting - Carcinoma Breast Clinical Trials

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

Start date: April 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of reconstructive complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream.